Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Genome & Company

More Like This

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement